2015 CTRC-AACR San Antonio Breast Cancer Symposium*

December 8-12, 2015; San Antonio, Texas
This program provides coverage of 2015 San Antonio Breast Cancer Symposium with downloadable slidesets and expert analysis of the most clinically relevant study results. Topics include the treatment of early and metastatic breast cancer, predictive biomarkers, and managing adverse events.
Mohammad Jahanzeb, MD, FACP
person default
Joyce O'Shaughnessy, MD

Breast Cancer

In this downloadable slideset, Mohammad Jahanzeb, MD, FACP, and Joyce O’Shaughnessy, MD, review key studies in early and advanced breast cancer presented at the 2015 San Antonio Breast Cancer Symposium

Released: January 11, 2016

Mohammad Jahanzeb, MD, FACP, and Joyce O’Shaughnessy, MD, provide their analysis of key presentations from the 2015 San Antonio breast cancer meeting.

Mohammad Jahanzeb, MD, FACP person default Joyce O'Shaughnessy, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: February 29, 2016 Expiration: February 28, 2017

Longer follow-up demonstrated that the addition of palbociclib to fulvestrant maintained a significant PFS improvement in patients with MBC.

Released: December 14, 2015

Abemaciclib combined with endocrine or HER2-targeted therapies was safe and active in patients with MBC.

Released: December 18, 2015

In this phase II trial, the use of paclitaxel with neratinib plus trastuzumab increased pCR rate vs paclitaxel and either anti-HER2 agent alone in women with HER2+ locally advanced breast cancer.

Released: December 13, 2015

Activity of investigational anti–PD-L1 monoclonal antibody in locally advanced or metastatic breast cancer is associated with PD-L1 expression.

Released: December 10, 2015

Phase III study of adjuvant capecitabine in patients with HER2-negative breast cancer and pathologic residual disease following standard anthracycline/taxane neoadjuvant chemotherapy.

Released: December 15, 2015

Adjuvant denosumab increased DFS in AI-treated postmenopausal women with early HR+ breast cancer.

Released: December 13, 2015

Adding carboplatin to neoadjuvant chemotherapy significantly improved DFS in triple-negative but not HER2+ early breast cancer.

Released: December 16, 2015

Greatest benefit seen in those with centrally confirmed HER2+ disease, completion of trastuzumab within 1 year of study entry, and hormone receptor–positive disease.

Released: December 14, 2015

Twelve weeks of trastuzumab emtansine therapy increased the rate of pCR in women with HER2+/HR+ early breast cancer compared with trastuzumab plus endocrine therapy.

Released: December 15, 2015

This long-term follow-up analysis demonstrated a sustained advantage of adjuvant therapy with trastuzumab-containing regimens over the non-trastuzumab control in patients with HER2+ early breast cancer.

Released: December 18, 2015

Use of trastuzumab emtansine improved survival in women with metastatic breast cancer and previous experience of anti-HER2 therapies compared with physician-selected therapy.

Released: December 14, 2015

Preliminary data show efficacy and manageable toxicity in 25 patients with PD-L1+, ER+/HER2- advanced breast cancer.

Released: December 15, 2015

The combination of the investigational PI3K inhibitor buparlisib with fulvestrant extended PFS in patients with HR+/HER2- advanced breast cancer who progressed on previous AI therapy.

Released: December 16, 2015

This single-arm phase II study demonstrated enhanced cell cycle arrest with the addition of palbociclib to neoadjuvant anastrozole in patients with ER+/HER2- early breast cancer.

Released: December 16, 2015

In patients with triple-negative breast cancer, 12 weeks of albumin-bound paclitaxel plus carboplatin significantly increased pCR rate vs albumin-bound paclitaxel plus gemcitabine.

Released: December 17, 2015

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?